PubRank

Carolyn Williamson

Author PubWeight™ 101.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006 5.25
2 The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011 4.18
3 Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008 3.40
4 Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009 2.70
5 Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog 2008 2.59
6 Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012 2.48
7 Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 2012 2.42
8 CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2006 2.32
9 The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2007 2.29
10 Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004 2.29
11 Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011 2.26
12 Dual HIV-1 infection associated with rapid disease progression. Lancet 2004 2.17
13 Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 2012 2.05
14 Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. AIDS 2013 2.04
15 Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002 1.97
16 Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010 1.94
17 Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med 2006 1.90
18 Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013 1.65
19 Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol 2009 1.49
20 Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis 2008 1.42
21 Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002 1.41
22 Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007 1.31
23 African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 2008 1.23
24 Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol 2008 1.20
25 Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 2012 1.17
26 Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 2013 1.15
27 Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol 2013 1.13
28 The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med 2012 1.12
29 Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006 1.10
30 Utilizing nucleic acid amplification to identify acute HIV infection. AIDS 2007 1.07
31 Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses 2007 1.06
32 HIV type 1 subtype C gag and nef diversity in Southern Africa. AIDS Res Hum Retroviruses 2007 1.05
33 Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 2008 1.05
34 Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression. J Virol 2010 1.04
35 Degenerate Primer IDs and the birthday problem. Proc Natl Acad Sci U S A 2012 1.04
36 Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses 2005 1.03
37 A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology 2009 1.02
38 CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis 2012 0.99
39 Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol 2007 0.98
40 Anaemia in acute HIV-1 subtype C infection. PLoS One 2008 0.96
41 HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses 2002 0.95
42 A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 2009 0.94
43 HIV molecular epidemiology: transmission and adaptation to human populations. Curr Opin HIV AIDS 2009 0.94
44 Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology 2011 0.93
45 Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic. Virol J 2013 0.93
46 Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol 2013 0.92
47 Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. PLoS One 2013 0.92
48 HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr 2015 0.90
49 Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 2003 0.90
50 A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 2008 0.90
51 Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells. J Immunol 2012 0.90
52 Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 2004 0.89
53 Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania. J Acquir Immune Defic Syndr 2010 0.89
54 Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009 0.88
55 Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol 2013 0.87
56 No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PLoS One 2013 0.86
57 HIV infection in high school students in rural South Africa: role of transmissions among students. AIDS Res Hum Retroviruses 2014 0.86
58 HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 2008 0.85
59 Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier. AIDS Res Hum Retroviruses 2011 0.85
60 Epidemiology of HIV-1 subtypes among men who have sex with men in Cape Town, South Africa. J Acquir Immune Defic Syndr 2014 0.85
61 Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms. Virology 2011 0.85
62 Preparing developing countries for efficacy trials. Curr Opin HIV AIDS 2006 0.84
63 South African HIV-1 vaccine candidates - the journey from the bench to clinical trials. S Afr Med J 2012 0.84
64 Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials. PLoS One 2011 0.84
65 Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. J Virol 2012 0.83
66 CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs. AIDS Res Hum Retroviruses 2007 0.82
67 Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J 2013 0.82
68 Investigation of HIV in amniotic fluid from HIV-infected pregnant women at full term. J Infect Dis 2005 0.82
69 Genetic characterization of HIV before widespread testing of HIV vaccine candidates at a clinical trial site in Pretoria, South Africa. AIDS Res Hum Retroviruses 2012 0.79
70 Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet 2002 0.79
71 Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women. AIDS 2004 0.78
72 Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. Virol J 2008 0.78
73 Approaches to the induction of HIV broadly neutralizing antibodies. Curr Opin HIV AIDS 2016 0.77
74 Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune Defic Syndr 2016 0.77
75 A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virol J 2011 0.76
76 The challenges of HIV vaccine development and testing. Best Pract Res Clin Obstet Gynaecol 2005 0.76
77 Early evolution of HLA-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C infected women. AIDS 2016 0.75
78 Response to 'single genome amplification and sequencing methods require appropriate thresholds for viral transmission and evolution studies'. AIDS 2014 0.75
79 Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. J Acquir Immune Defic Syndr 2017 0.75
80 Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog 2017 0.75